RxDoctor Payments Data

Charles Reed, MD

Family Medicine · Winnsboro, LANPI 1013919604

Payments from drug & device makers

$13,063in general payments, 2019–2025

Across 802 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • AbbVie$1K
  • Lilly USA, LLC$958
  • GSK$822
  • Amgen$673
  • plus $6K from 35 others

What the payments were for

  • Food & beverage$13,034100%
  • Education$290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,063 in reported general payments places this provider in the 95th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$320,752
Medicare patients
435
Services billed
11,989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban198$146,726
JardianceEmpagliflozin124$109,601
OzempicSemaglutide79$101,422
KerendiaFinerenone109$81,225
EntrestoSacubitril/Valsartan90$75,488
FarxigaDapagliflozin Propanediol71$63,957
MounjaroTirzepatide53$63,871
Trelegy ElliptaFluticasone/Umeclidin/Vilanter59$39,089
TrulicityDulaglutide34$35,994
MyrbetriqMirabegron71$35,701
JanuviaSitagliptin Phosphate35$23,111
XareltoRivaroxaban26$19,077
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$13,081
Soliqua 100-33Insulin Glargine/Lixisenatide12$10,368
DapagliflozinDapagliflozin Propanediol17$8,428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$279$146,726198 claims
Boehringer IngelheimJardiance$653$109,601124 claims
Novo NordiskOzempic$1,443$101,42279 claims
Lilly USA, LLCMounjaro, Trulicity$958$99,86587 claims
BayerKerendia$376$81,225109 claims
NovartisEntresto$416$75,48890 claims
AstraZenecaFarxiga, Symbicort$1,555$67,76884 claims
GSKTrelegy Ellipta$822$39,08959 claims
Astellas Pharma US IncMyrbetriq$303$35,70171 claims
MerckJanuvia$448$23,11135 claims
Johnson & JohnsonXarelto$640$19,07726 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$103$10,36812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Winnsboro

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →